Core Viewpoint - Bio-Path is advancing its product candidate Prexigebersen for the targeted treatment of acute myeloid leukemia (AML), with recent interim data from its Phase 2 clinical trial showing promising results [1][4]. Group 1: Clinical Trial Data - The ongoing trial of Prexigebersen demonstrates good tolerance with few adverse events reported [4]. - Compelling efficiency data is beginning to emerge for AML patients participating in the trial [4]. Group 2: Stock Performance - Bio-Path's stock (NASDAQ: BPTH) has seen a significant increase of 19.5% as of Friday morning, reflecting positive investor sentiment following the clinical trial data release [4]. - The trading volume for BPTH stock has surged, with over 4.3 million shares traded, significantly above its average daily volume of approximately 2.4 million shares [7].

In Cohort 1, 31 newly diagnosed patients were enrolled; 20 evaluable patients (9 male: 45%) with a median age of 75 years (range, 69 - 84), treated with at least one cycle of prexigebersen, decitabine and venetoclax, had adverse-risk (n=12, 2017 ELN guidelines) or secondary AML (sAML; n=7) evolved from myelodysplastic syndromes (n=4), chronic myelomonocytic leukemia (n=1) or treatment-related AML (n=2). Fifteen patients (75% of evaluable; 54% of enrolled) achieved complete remission (CR), CRh (CR with parti ...

Core Viewpoint - Bio-Path Holdings, Inc. has successfully closed a private placement, raising approximately $4.0 million through the issuance of shares and warrants, aimed at supporting its biotechnology initiatives in cancer treatment [1][2]. Group 1: Private Placement Details - The company issued a total of 1,809,955 shares of common stock and corresponding series A and series B warrants, with a purchase price of $2.21 per share [1]. - The series A warrants have an exercise price of $2.00 per share and are valid for five years, while the short-term series B warrants also have the same exercise price but expire in twenty-four months [1]. - H.C. Wainwright & Co. served as the exclusive placement agent for this offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering are intended for working capital and general corporate purposes [2]. Group 3: Company Overview - Bio-Path is focused on developing its proprietary DNAbilize® technology, which facilitates the creation of targeted nucleic acid cancer drugs [5]. - The lead product candidate, prexigebersen (BP1001), is currently in a Phase 2 study for blood cancers, while BP1001-A is in a Phase 1/1b study for solid tumors [5]. - The company is also advancing BP1002, targeting the Bcl-2 protein for blood cancers and solid tumors, and plans to file an IND application for BP1003, a novel STAT3 antisense oligodeoxynucleotide [5].

Key Points - Bio-Path Holdings, Inc. (NASDAQ: BPTH) is currently advancing its Prexigebersen Phase 2 clinical trial [2] - The company has a diverse pipeline with numerous drug candidates under development [2] - Bio-Path has successfully raised $3.5 million in 2024, providing sufficient liquidity for its operations [2]

HOUSTON, June 04, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ:BPTH) ("Bio-Path" or the "Company"), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,809,955 shares of its common stock (or common stock equivalents in lieu thereof), series A warrants to purchase up to 1,8 ...

HOUSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, presented interim results from the Company's Phase 2 study of prexigebersen (BP1001) in combination with decitabine and venetoclax for the treatment of acute myeloid leukemia (AML) in an oral presentation at the American Society of Clinical Oncology (ASCO) Annu ...

Jorge Cortes, M.D., Director of the Georgia Cancer Center, will present interim results from the Company's Phase 2 study of prexigebersen (BP1001) in combination with decitabine and venetoclax for the treatment of acute myeloid leukemia (AML). The data show prexigebersen continues to be well-tolerated and has now demonstrated compelling efficacy results in two reporting cohorts including evaluable newly diagnosed AML patients and evaluable refractory/relapsed AML patients, both of which exceeded outcomes wi ...

Core Insights - Bio-Path Holdings, Inc. is set to present interim results from its Phase 2 study of prexigebersen (BP1001) for acute myeloid leukemia (AML) at the 2024 European Hematology Association Congress [1][2][3] Company Overview - Bio-Path Holdings, Inc. is a biotechnology company focused on developing targeted nucleic acid cancer drugs using its proprietary DNAbilize® liposomal delivery and antisense technology [1][4] - The lead product candidate, prexigebersen (BP1001), targets the Grb2 protein and is currently in a Phase 2 study for blood cancers [4] - The company is also developing BP1002, which targets the Bcl-2 protein, and BP1003, a novel liposome-incorporated STAT3 antisense oligodeoxynucleotide [4] Clinical Study Insights - The interim results presented by Dr. Jorge Cortes indicate that prexigebersen is well-tolerated and shows compelling efficacy in newly diagnosed and refractory/relapsed AML patients, outperforming frontline therapy [2][3] - The poster presentation is scheduled for June 14, 2024, at 6:00 PM CEST, at IFEMA Madrid Recinto Ferial, Hall 7, with the abstract number P536 [3]

HOUSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced an upcoming oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 - June 4, 2024 in Chicago, IL. Maro Ohanian, D.O., Department of Leukemia, University of Texas MD Anderson Cancer Center, will p ...

Bio-Path Holdings Inc. (NASDAQ:BPTH) Q1 2024 Earnings Conference Call May 15, 2024 8:30 AM ET Company Participants Will O'Connor - Stern Investor Relations Peter Nielsen - Chief Executive Officer and Chief Financial Officer Anthony Price - Senior Vice President of Finance, Accounting and Administration Operator Good morning ladies and gentlemen. Welcome to the Bio-Path Holdings First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. Following the formal remarks ...